Literature DB >> 25531553

Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice.

M Aguilera1, M Cerdà-Cuéllar, V Martínez.   

Abstract

Alterations in the composition of the commensal microbiota (dysbiosis) seem to be a pathogenic component of functional gastrointestinal disorders, mainly irritable bowel syndrome (IBS), and might participate in the secretomotor and sensory alterations observed in these patients.We determined if a state antibiotics-induced intestinal dysbiosis is able to modify colonic pain-related and motor responses and characterized the neuro-immune mechanisms implicated in mice. A 2-week antibiotics treatment induced a colonic dysbiosis (increments in Bacteroides spp, Clostridium coccoides and Lactobacillus spp and reduction in Bifidobacterium spp). Bacterial adherence was not affected. Dysbiosis was associated with increased levels of secretory-IgA, up-regulation of the antimicrobial lectin RegIIIγ, and toll-like receptors (TLR) 4 and 7 and down-regulation of the antimicrobial-peptide Resistin-Like Molecule-β and TLR5. Dysbiotic mice showed less goblet cells, without changes in the thickness of the mucus layer. Neither macroscopical nor microscopical signs of inflammation were observed. In dysbiotic mice, expression of the cannabinoid receptor 2 was up-regulated, while the cannabinoid 1 and the mu-opioid receptors were down-regulated. In antibiotic-treated mice, visceral pain-related responses elicited by intraperitoneal acetic acid or intracolonic capsaicin were significantly attenuated. Colonic contractility was enhanced during dysbiosis. Intestinal dysbiosis induce changes in the innate intestinal immune system and modulate the expression of pain-related sensory systems, an effect associated with a reduction in visceral pain-related responses. Commensal microbiota modulates gut neuro-immune sensory systems, leading to functional changes, at least as it relates to viscerosensitivity. Similar mechanisms might explain the beneficial effects of antibiotics or certain probiotics in the treatment of IBS.

Entities:  

Keywords:  AMP, antimicrobial peptide; CB1/2, cannabinoid receptor type 1 or 2; FGD, functional gastrointestinal disorder; FISH, fluorescent in situ hybridization; GCM, gut commensal microbiota; GI, gastrointestinal; IBS, irritable bowel syndrome; MOR, mu-opioid receptor; NGF, nerve growth factor; PPR, pattern recognition receptor; RELMβ, resistin-like molecule-β; RT-qPCR, reverse transcription quantitative polymerase chain reaction; Reg3γ, regenerating islet-derived protein 3 gamma; SFB, segmented filamentous bacteria; TLR, toll-like receptor; TPH 1/2, tryptophan hydroxylase isoforms 1 or 2; TRPV1/3, transient receptor potential vanilloid types 1 or 3; cannabinoid receptors; colonic motility; gut commensal microbiota; iNOS, inducible nitric oxide synthase; innate immune system; intestinal dysbiosis; opioid receptors; sIgA, secretory IgA; visceral sensitivity

Mesh:

Substances:

Year:  2015        PMID: 25531553      PMCID: PMC4615720          DOI: 10.4161/19490976.2014.990790

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  64 in total

1.  Antibiotics conspicuously affect community profiles and richness, but not the density of bacterial cells associated with mucosa in the large and small intestines of mice.

Authors:  Nathan J Puhl; Richard R E Uwiera; L Jay Yanke; L Brent Selinger; G Douglas Inglis
Journal:  Anaerobe       Date:  2011-12-13       Impact factor: 3.331

Review 2.  The immune system and the gut microbiota: friends or foes?

Authors:  Nadine Cerf-Bensussan; Valérie Gaboriau-Routhiau
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

3.  Immunology. The gut's Clostridium cocktail.

Authors:  Michael J Barnes; Fiona Powrie
Journal:  Science       Date:  2011-01-21       Impact factor: 47.728

4.  Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.

Authors:  S Guglielmetti; D Mora; M Gschwender; K Popp
Journal:  Aliment Pharmacol Ther       Date:  2011-03-21       Impact factor: 8.171

Review 5.  Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation.

Authors:  Pilar M Domínguez; Carlos Ardavín
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

6.  Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis.

Authors:  M Wlodarska; B Willing; K M Keeney; A Menendez; K S Bergstrom; N Gill; S L Russell; B A Vallance; B B Finlay
Journal:  Infect Immun       Date:  2011-02-14       Impact factor: 3.441

7.  Characterization of housing-related spontaneous variations of gut microbiota and expression of toll-like receptors 2 and 4 in rats.

Authors:  Evangelina Terán-Ventura; Mercè Roca; Maria Teresa Martin; Maria Lourdes Abarca; Vicente Martinez; Patri Vergara
Journal:  Microb Ecol       Date:  2010-08-18       Impact factor: 4.552

Review 8.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287

9.  Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression.

Authors:  Dag Henrik Reikvam; Alexander Erofeev; Anders Sandvik; Vedrana Grcic; Frode Lars Jahnsen; Peter Gaustad; Kathy D McCoy; Andrew J Macpherson; Leonardo A Meza-Zepeda; Finn-Eirik Johansen
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.

Authors:  Jutta Zwielehner; Cornelia Lassl; Berit Hippe; Angelika Pointner; Olivier J Switzeny; Marlene Remely; Elvira Kitzweger; Reinhard Ruckser; Alexander G Haslberger
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more
  31 in total

Review 1.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 2.  Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Authors:  Eleonora Distrutti; Lorenzo Monaldi; Patrizia Ricci; Stefano Fiorucci
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 3.  Irritable bowel syndrome, the microbiota and the gut-brain axis.

Authors:  Hans Raskov; Jakob Burcharth; Hans-Christian Pommergaard; Jacob Rosenberg
Journal:  Gut Microbes       Date:  2016-07-29

4.  µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients.

Authors:  Giovanni Dothel; Lin Chang; Wendy Shih; Maria Raffaella Barbaro; Cesare Cremon; Vincenzo Stanghellini; Fabrizio De Ponti; Emeran A Mayer; Giovanni Barbara; Catia Sternini
Journal:  Neurogastroenterol Motil       Date:  2019-07-23       Impact factor: 3.598

5.  Preexisting Commensal Dysbiosis Is a Host-Intrinsic Regulator of Tissue Inflammation and Tumor Cell Dissemination in Hormone Receptor-Positive Breast Cancer.

Authors:  Claire Buchta Rosean; Raegan R Bostic; Joshua C M Ferey; Tzu-Yu Feng; Francesca N Azar; Kenneth S Tung; Mikhail G Dozmorov; Ekaterina Smirnova; Paula D Bos; Melanie R Rutkowski
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

Review 6.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

7.  Influences of Gastrointestinal Microbiota Dysbiosis on Serum Proinflammatory Markers in Epithelial Ovarian Cancer Development and Progression.

Authors:  Diane E Mahoney; Prabhakar Chalise; Faith Rahman; Janet D Pierce
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

Review 8.  Stress and the Microbiota-Gut-Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome.

Authors:  Rachel D Moloney; Anthony C Johnson; Siobhain M O'Mahony; Timothy G Dinan; Beverley Greenwood-Van Meerveld; John F Cryan
Journal:  CNS Neurosci Ther       Date:  2015-12-10       Impact factor: 5.243

Review 9.  Animal models of visceral pain and the role of the microbiome.

Authors:  Christine West; Karen-Anne McVey Neufeld
Journal:  Neurobiol Pain       Date:  2021-05-28

Review 10.  The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease.

Authors:  C Hasenoehrl; U Taschler; M Storr; R Schicho
Journal:  Neurogastroenterol Motil       Date:  2016-08-26       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.